Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females.
Humans
Male
Female
Opioid-Related Disorders
/ genetics
Adult
Black or African American
/ genetics
White People
/ genetics
Alleles
Self Report
Middle Aged
Caribbean Region
Genetic Predisposition to Disease
/ genetics
Cytochrome P-450 CYP3A
/ genetics
Polymorphism, Single Nucleotide
/ genetics
Risk Factors
Black People
/ genetics
Journal
The pharmacogenomics journal
ISSN: 1473-1150
Titre abrégé: Pharmacogenomics J
Pays: United States
ID NLM: 101083949
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
14
07
2023
accepted:
15
05
2024
revised:
02
05
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
1
8
2024
Statut:
epublish
Résumé
The influence of genetic variants related to opioid use disorder (OUD) was evaluated using multiple logistic regression analysis in self-reported assigned African American/Afro-Caribbean and European biogeographical ancestry groups (BGAGs) and by sex. From a sample size of 1301 adult patients (>18 years of age) seen in emergency departments of three medical centers in Ohio, six variants were found to be associated with OUD. Two of the variants, rs2740574 (CYP3A4) and rs324029 (DRD3), were included in the analysis having met criteria of at least five subjects for each BGAG, variant carrier status, and OUD status combinations. Variant carriers in the African/Afro-Caribbean BGAG had slightly lower predicted probabilities of OUD. Variant carriers in the European BGAG had slightly higher predicted probabilities of OUD. Relative to sex, all the six variants met evaluation criteria (five subjects for all sex, variant, and OUD status combinations). No statistically significant interactions were found between a given variant, BGAGs and sex. Findings suggest variant testing relative to OUD risk can be applied across BGAGs and sex, however, studies in larger populations are needed.
Identifiants
pubmed: 39090078
doi: 10.1038/s41397-024-00337-y
pii: 10.1038/s41397-024-00337-y
doi:
Substances chimiques
Cytochrome P-450 CYP3A
EC 1.14.14.1
CYP3A4 protein, human
EC 1.14.14.55
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23Informations de copyright
© 2024. The Author(s).
Références
Messent P. DSM-5. Clin Child Psychol Psychiatry. 2013;18:479–82.
pubmed: 24052569
Keyes KM, Rutherford C, Hamilton A, Barocas JA, Gelberg KH, Mueller PP, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022;3:100052 https://doi.org/10.1016/j.dadr.2022.100052 .
doi: 10.1016/j.dadr.2022.100052
pubmed: 35783994
pmcid: 9248998
Centers for Disease Control and Prevention (CDC). U.S. overdose deaths in 2021 increased half as much as in 2020 – but still up 15%. 2022. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm .
Kaiser Family Foundation. Opioid overdose deaths by race/ethnicity. 2021. Available from: https://www.kff.org/other/state-indicator/opioid-overdose-deaths-by-raceethnicity/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D .
Soares WE, Melnick ER, Nath B, D’Onofrio G, Paek H, Skains RM, et al. Emergency Department Visits for Nonfatal Opioid Overdose During the COVID-19 Pandemic Across Six US Health Care Systems. Ann Emerg Med. 2022;79:158–67.
doi: 10.1016/j.annemergmed.2021.03.013
pubmed: 34119326
Centers for Disease Control and Prevention (CDC). Drug Overdose Mortality by State. 2022. Available from: https://www.cdc.gov/nchs/pressroom/sosmap/drug_poisoning_mortality/drug_poisoning.htm .
Freiermuth CE, Kisor DF, Lambert J, Braun R, Frey JA, Bachmann DJ, et al. Genetic Variants Associated with Opioid Use Disorder. Clin Pharmacol Ther. 2023;113:1089–95.
doi: 10.1002/cpt.2864
pubmed: 36744646
Kuo SC, Yeh YW, Chen CY, Huang CC, Chang HA, Yen CH, et al. DRD3 variation associates with early-onset heroin dependence, but not specific personality traits. Prog Neuropsychopharm Biol Psychiatry. 2014;51:1–8.
doi: 10.1016/j.pnpbp.2013.12.018
Ishida T, Naito T, Sato H, Kawakami J. Relationship between the plasma fentanyl and serum 4beta-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain. Drug Metab Pharmacokinet. 2016;31:242–8.
doi: 10.1016/j.dmpk.2016.04.001
pubmed: 27236640
Zhang H, Yang Q, Zheng W, Ouyang Y, Yang M, Wang F, et al. CYP gene family variants as a potential risk factors in drug addiction in Han Chinese. J Gene Med. 2016;18:147–53.
doi: 10.1002/jgm.2887
pubmed: 27257124
Huddart R, Fohner AE, Whirl-Carrillo M, Wojcik GL, Gignoux CR, Popejoy AB, et al. Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. Clin Pharmacol Ther. 2019;105:1256–62.
doi: 10.1002/cpt.1322
pubmed: 30506572
Pharmacogenomics Knowledgebase Blog. Response to the American Academy of Pediatrics’ statement “Eliminating race-based Medicine”. 2022. Available from: https://pharmgkb.blogspot.com/2022/05/response-to-american-academy-of.html .
Bright D, Langerveld A, DeVuyst-Miller S, Saadeh C, Choker A, Lehigh E, et al. Identification of a sex-stratified genetic algorithm for opioid addiction risk. Pharmacogenomic J. 2021;3:326–35.
doi: 10.1038/s41397-021-00212-0
Schuler MS, Schell TL, Wong EC. Racial/ethnic differences in prescription opioid misuse and heroin use among a national sample, 1999-2018. Drug Alcohol Depend. 2021;221:108588 https://doi.org/10.1016/j.drugalcdep.2021.108588 .
doi: 10.1016/j.drugalcdep.2021.108588
pubmed: 33639569
pmcid: 8026521
Crist RC, Reiner BC, Berrettini WH. A review of opioid addiction genetics. Curr Opin Psychol. 2019;27:31–35.
doi: 10.1016/j.copsyc.2018.07.014
pubmed: 30118972
The pharmacogenomics Knowledgebase. Per variant. 2023. Available from: https://www.pharmgkb.org/ .
GenomAD browser. 2023. Available from: https://gnomad.broadinstitute.org/about .
Sanchez-Roige S, Fontanillas P, Jennings MV, Bianchi SB, Huang Y, Hatoum AS, et al. Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry. Mol Psychiatry. 2021;26:6209–17.
doi: 10.1038/s41380-021-01335-3
pubmed: 34728798
pmcid: 8562028
Gaddis N, Mathur R, Marks J, Zhou L, Quach B, Waldrop A, et al. Multi-trait genome-wide association study of opioid addiction: OPRM1 and beyond. Sci Rep. 2022;12:16873 https://doi.org/10.1038/s41598-022-21003-y .
doi: 10.1038/s41598-022-21003-y
pubmed: 36207451
pmcid: 9546890
Deak JD, Zhou H, Galimberti M, Levey DF, Wendt FR, Sanchez-Roige S, et al. Genome-wide association study in individuals of European and African ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-wide significant risk loci. Mol Psychiatry. 2022;27:3970–9.
doi: 10.1038/s41380-022-01709-1
pubmed: 35879402
pmcid: 9718667
Huddart R, Sangkuhl K, Whirl-Carrillo M, Klein TE. Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic? Clin Pharmacol Ther. 2019;106:284–6.
doi: 10.1002/cpt.1420
pubmed: 30977517
Ettienne EB, Ofoegbu A, Maneno MK, Briggs J, Ezeude G, Williams S, et al. Pharmacogenomics and Opioid Use Disorder: Clinical Decision Support in an African American Cohort. J Natl Med Assoc. 2011;111:674–81.
Ettienne EB, Chapman E, Maneno M, Ofoegbu A, Wilson B, Settles-Reaves B, et al. Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach. Addict Behav Rep. 2017;6:8–14.
pubmed: 29450233
pmcid: 5800559
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Human Genome Project, 2001. The human genome. Nature. 2001;409:860–921.
pubmed: 11237011
Witherspoon DJ, Wooding S, Rogers AR, Marchani EE, Watkins WS, Batzer MA, et al. Genetic similarities within and between human populations. Genetics. 2007;176:351–9.
doi: 10.1534/genetics.106.067355
pubmed: 17339205
pmcid: 1893020
Sampson JN, Kidd KK, Kidd JR, Zhao H. Selecting SNPs to identify ancestry. Ann Hum Genet. 2011;75:539–53.
doi: 10.1111/j.1469-1809.2011.00656.x
pubmed: 21668909
pmcid: 3141729
Mersha TB, Abebe T. Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Hum Genomics. 2015;9:1 https://doi.org/10.1186/s40246-014-0023-x .
doi: 10.1186/s40246-014-0023-x
pubmed: 25563503
pmcid: 4307746
Mezzalira S, Toffoli G. The effects of sex on pharmacogenetically guided drug treatment. Pharmacogenomics. 2021;22:959–62.
doi: 10.2217/pgs-2021-0088
pubmed: 34545749
Lopes GS, Lopes JL, Bielinski SJ, Armasu SM, Zhu Y, Cavanaugh DC, et al. Identification of sex-specific genetic associations in response to opioid analgesics in a White, non-Hispanic cohort from Southeast Minnesota. Pharmacogenomics J. 2022;22:117–23.
doi: 10.1038/s41397-022-00265-9
pubmed: 35102242
pmcid: 8975736
Lopes GS, Bielinski SJ, Moyer AM, Black Iii JL, Jacobson DJ, Jiang R, et al. Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics. Pharmgenomics Pers Med. 2020;13:71–79.
pubmed: 32214840
pmcid: 7081062
Palma-Gudiel H, Peralta V, Deuschle M, Navarro V, Fañanás L. Epigenetics-by-sex interaction for somatization conferred by methylation at the promoter region of SLC6A4 gene. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:125–31.
doi: 10.1016/j.pnpbp.2018.09.002
pubmed: 30201454
Peltier MR, Sofuoglu M, Petrakis IL, Stefanovics E, Rosenheck RA. Sex Differences in Opioid Use Disorder Prevalence and Multimorbidity Nationally in the Veterans Health Administration. J Dual Diagn. 2021;17:124–34.
doi: 10.1080/15504263.2021.1904162
pubmed: 33982642
pmcid: 8887838
Huhn AS, Berry MS, Dunn KE. Review: Sex-Based Differences in Treatment Outcomes for Persons With Opioid Use Disorder. Am J Addict. 2019;28:246–61.
doi: 10.1111/ajad.12921
pubmed: 31131505
pmcid: 6591072